To study the role of mutant p53 in the induction and cure of tumors, we generated transgenic mice carrying mutant p53 (mp53) containing a 9 bp deletion in exon 6 in addition to wild-type p53, expressing both p53 and mp53. The mp53 cDNA was cloned from a radiation-induced mouse tumor and ligated to the chicken b-actin promoter/CMV-IE enhancer in the expression vector. The presence of mp53 suppressed p21 expression in primary fibroblasts after ionizing irradiation, indicating the dominant-negative activity of mp53 in the mice. These mice developed fibrosarcomas after the subcutaneous injection of 3-methylcholanthrene with an incidence 1.7-fold higher than that of wild-type mice (42% excess). The tumors were then treated via a potent atelocollagen delivery system with small interfering RNA (siRNA), that targeted the promoter/enhancer of the expression vector, resulting in the suppression of tumor growth in 30% of 44 autochthonous tumors, including four cures, and their transplants, the total fraction corresponding to the tumor excess. This suppressive effect involved the induction of apoptosis. These results indicate that mp53 activity causes tumors that can be suppressed by subsequent silencing of mp53 in the presence of wild-type p53 alleles.
Introduction
The p53 gene is a tumor suppressor, controlling the cell cycle and apoptosis, 1, 2 protecting the irradiated mouse fetus from teratogenesis 3 and regulating mouse reproduction. 4 Mutated p53 is frequently found in human cancers. 5 and predisposes Li-Fraumeni syndrome patients to cancer. 6 Heterozygous mice with various p53 mutations have been used to study the effects of these mutations on tumor induction. Mice carrying p53 mutated at codon135 are highly sensitive to spontaneous 7, 8 and chemical tumor induction. 9 Mice carrying p53 mutations analogous to the human Li-Fraumeni syndrome hot spot mutation exhibit a high incidence of spontaneous tumors with a spectrum different from that of p53-null mice, [10] [11] [12] a high metastatic potential for produced tumors 13 and a high incidence of chemically induced tumors. 14 Especially of note is an approach toward simulating the human context with heterozygous mice containing human p53 and Li-Fraumeni mutant p53 in the genome. 12 At the initial step of carcinogenesis caused by p53 mutation, there must exist a heterozygous state of wildtype p53 with mutant p53, resulting in the expression of both types of p53 proteins. Mutant p53 proteins act in a dominant-negative manner by interfering with the activity of wild-type p53 proteins, thus exerting gain-of-function activity. 12, 15, 16 This activity induces tumor formation by interfering with the ATM-controlled molecular network protecting cells from tumorigenesis. A recent study reported that mutant p53 interferes with the binding of the repair protein complex, Mre11-Rad50-NBS1, to radiation-induced DNA double strand breaks, 12 suggesting an additional role of mutant p53 in DNA repair and tumorigenesis.
On the other hand, the absence of p53 expression in mice results in a high incidence of tumors. 17, 18 By restoring wild-type p53 function via Cre recombinasemediated reactivation, such tumors regress after apoptosis 19 or cellular senescence. 20 However, such restoration may not function in the presence of mutant p53 protein because of its dominant-negative action over the wild-type. The remaining wild-type p53 allele is often lost in the tumors of p53-heterozygous hosts 6 ; therefore, curing tumors by restoring wild-type p53 activity cannot be expected.
Curing autochthonous tumors in experimental animals induced either spontaneously, chemically or with radiation, is an essential approach to achieving a true cure for cancer. 21 Mouse fibrosarcomas induced by 3-methylcholanthrene (MCA) are a suitable model for experimental therapy, because of their well-characterized growth kinetics. 22 Curing autochthonous MCA-induced tumors with ionizing radiation is very difficult; after temporary regression, most regrow with the same clonal nature of the primary tumor, whereas transplanted tumors of the same origin are easily cured with 44 Gy of the dose needed to cure 50% of tumors. 23, 24 This discrepancy may be explained by the differences in adaptive immunity between autochthonous and transplanted tumor environments. 25 Therefore, our final targets for cure experiments are autochthonous tumors.
Gene silencing by RNA interference is a promising approach for suppressing tumors. 26 In our transgenic mice, mutant p53 cDNA was introduced in addition to intact wild-type p53 alleles; thus the loss of the wild-type p53 allele frequently observed in the tumors of mutant p53-heterozygous mice is unlikely to occur. Using this advantage, we attempted to silence only the mutant p53 transgene, not wild-type p53, using siRNA designed to target the promoter/enhancer of the transgene. If the mutant p53 causes the tumors, it should respond to silencing to an appreciable extent and consequently regress or stop growing.
The effective silencing of transcription by targeting a promoter with siRNA has been shown in cultured human cells to involve DNA methylation of the targeted sequence 27 and the interference of the formation of the transcription-initiation complex with Argonaute proteins leading to heterochromatin formation. 28 In this study, we used siRNA designed to suppress the promoter/enhancer of the mutant p53 transgene. Atelocollagen, an end-cut collagen, was used as a delivery system to protect siRNA from RNase and introduce siRNA efficiently to the target molecules in the tumor tissue. 29, 30 We report here the construction of transgenic mice carrying intact wild-type p53 and mutant p53 cDNA, being homozygous for the wild-type p53 allele and hemizygous for mutant p53 (p53 þ / þ ; m ). For the sake of convenience, we refer to the p53 þ / þ ; m mice as mp53 mice. The presence of mutant p53 elevated tumor incidence in the presence of intact wild-type p53 alleles, and these tumors could be suppressed by silencing the mutant p53 transgene through the reactivation of apoptotic activity.
Materials and methods
Cloning of mutant p53 cDNA and construction of pTE50 The original tumor carrying the mutant p53 was squamous cell carcinoma, chosen from mouse skin tumors with various p53 mutations generated by repeated b-irradiation. 31 Mutant p53 cDNA with a 9 bp deletion from codon 191-193 in exon 6 of the p53 gene, corresponding to the DNA-binding domain of p53, was prepared from the tumor. 32 The XhoI/KpnI fragment of the mutant p53 cDNA, which included the deletion, was first cloned into pBR322, then this fragment was exchanged with the corresponding fragment of the mouse p53 cDNA clone (RDB1284; Riken, Tsukuba, Japan) containing the exon 2-11 reading frame. The mutant p53 cDNA fragment cut by HindIII/XhoI was then inserted downstream of the chicken b-actin gene promoter combined with the CMV-IE enhancer in the 5.8 kb expression vector pCXN2 33 to construct pTE50 ( Figure 1a) . The DNA nucleotide sequence was determined using Big Dye Terminator v3.1 and ABI Prism 310 analyzer (Applied Biosystems, Warrington, WA) with p53 primers 32 according to the manufacturer's protocol. The expression of mp53 proteins was confirmed in cultured HEK293 cells harboring pTE50 (Supplementary Figure 1) .
Transgenic mice
The BamHI and PvuI digests of pTE50 containing mp53 cDNA were introduced into the early-stage embryos of C57BL/6J-Jcl mice (Oriental Yeast, Tokyo, Japan). Out of 105 candidate mice from 569 transplanted embryos, 2 transgenic mice, 1 male and 1 female, with mutant p53 were obtained. The male mp53 mouse was mated to wildtype C57BL/6J female mice to yield transgenic mp53 offspring. Mice were maintained according to the National Institute of Radiological Sciences guidelines for animal care. The mice were registered as C57BL/6J-Tg(pTE50)Nrs and frozen embryos were preserved at Riken BioResource Center (Riken).
Southern blot analysis and PCR genotyping of mouse DNA The DNA was extracted from mp53 mouse tails using phenol/chloroform after proteinase K (Invitrogen, Carlsbad, CA) digestion at 50 1C overnight, followed by ethanol precipitation. To confirm the presence of mp53, the DNA was subjected to Southern blot analysis with vector probe p1 after digestion with HindIII (Figure 1b ). For genotyping, 1 ml of 100-fold diluted cell lysates was directly applied to PCR in a 20 ml reaction mixture (Ex Taq; Takara Bio, Tokyo, Japan). The PCR reactions were performed in a thermal cycler (Gene Amp 9700; Applied Biosystems, Foster City, CA) for 30 cycles of 94 1C for 30 s, 55 1C for 30 s and 72 1C for 30 s. The PCR products were analyzed by 1% agarose gel electrophoresis.
mRNA-selective PCR
The mRNA-selective PCR utilized deoxyribonucleotide triphosphate analogs as precursors with low annealing and low denaturation temperatures to avoid the amplification of contaminating genomic DNA while synthesizing cDNA. 34 Total RNA was extracted from tissue using Qiagen MiniPrep kit (Qiagen, Hilden, Germany) and 0.35 mg was reverse transcribed to cDNA in a 25 ml Figure 2) , and the quantitative range was used to observe the effect of siRNA on mp53 mRNA expression.
PCR primers
The PCR primers used were the p53 exon 10 primer g14, 5 0 -AGGATGCCCATGCTACAGAG-3 0 and the vector primer 5KR, 5 0 -AGCCAGAAGTCAGATGCTCA-3 0 to detect the genomic mp53 and its cDNA; the exon 2 primer a0, 5 0 -ATGACTGCCATGGAGTCACA-3 0 in combination with 5KR to detect the full length of the exon 2-11 reading frame of mp53 cDNA; b1 in exon 4, 5 0 -CCATCACCTCACTGCATGGA-3 0 and 49R spanning the 9 bp deletion in exon 6, 5 0 -TTCCACCCTGATAAG ATGCTG-3 0 to detect wild-type p53 cDNA; I5-3 0 in intron 5, 5
0 -GGAATTCCTAAGAGCAAGAATAAGT CAGAA-3 0 in combination with b1 to detect genomic wild-type p53; ex1 in the 3 0 end of exon 1, 5 0 -CAGGC TTCTCCGAAGACTGG-3 0 and ex11hR, 5 0 -CTGAAG TCATAAGACAGCAA-3 0 to detect the full length of exon 2-exon 11 of wild-type p53 cDNA. Other p53 primers for sequencing are described elsewhere. 32 Primers to detect p21 cDNA were B, 5
0 -TAAAGGGCATCCT GAGCTACACT-3 0 and BR, 5 0 -TTACTCCTTCGAGGC CATGTAGG-3 0 ; and primers to detect mouse b-actin cDNA were F4, 5
0 -CTAGACTTCGAGCAGGAGAT GG-3 0 and R2, 5 0 -CAGAACAGTCCGCCTAGAAGC-3 0 .
Analysis of p21 protein in irradiated fetal mouse cells
Embryonic fibroblasts from transgenic and wild-type mice were cultured separately in Dulbecco's modified . Arrows g14 and 5KR indicate PCR primers for genotyping and mRNA-selective PCR. p1: a Southern blot probe. Restriction sites: B, BamHI; H, HindIII; K, KpnI; P, PvuI; X, XhoI. pTE50 cut with BamHI and PvuI (5.4 kb) was introduced into the mouse genome. (b) Representative blot and gels for mouse tail DNA. HindIII-cut genomic DNA was electrophoresed and hybridized with probe p1. HindIII-cut pTE50 was used as a position marker for Southern blot. PCR primer pairs: g14 and 5kR for the detection of exon 10-11 mp53, b1 and I5-3 0 for exon 4-intron 5 wild-type p53, and B and BR for p21. (c) mRNA-selective PCR profiles for liver tissues and tumors from mp53 and wild-type mice. Primer pairs: a0 and 5KR for exon 2-11 mp53 in the liver (1166 bp) and g14 and 5KR for exon 10-11 mp53 in the tumor; b1 and 49R for exon 4-6 wild-type p53, B and BR for p21, and F4 and R2 for mouse b-actin. (d) Electropherograms showing the 9 bp deletion from codon 191 to codon 193 in exon 6 in the cDNA of the liver of mp53 mice (upper) and its presence in the cDNA of the wild-type mouse liver (lower). cDNAs for sequencing were amplified by PCR with primer sets a0 and 5KR for mp53, and ex1 and ex11R for wild-type p53.
Silencing mutant p53 transgene to suppress tumors H Tanooka et al Eagle's medium (Sigma, St Louis, MO) supplemented with 10% fetal bovine serum (Calbiochem/Merck, Darmstadt, Germany) and 60 mg ml À1 kanamycin in a humidified CO 2 incubator at 37 1C. Cells were seeded at a density of 2.9 Â 10 5 cells in a 9 cm diameter culture dish, grown to a late log growth phase, irradiated by a 200 KVp X-ray generator (Shimazu PANTAK, Model M251-0468, Kyoto, Japan; filter: 0.5 mm Cu and 0.5 mm Al; dose rate 0.52 Gy min À1 ), incubated further in fresh medium, and collected at different time intervals. Proteins were then extracted using SDS buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol and 1% 2-mercaptoethanol). A portion of 20 ml of 2 mg ml À1 protein was loaded on 12% SDS-polyacrylamide gel electrophoresis, transferred to an Immobilon-P membrane (Millipore, Bedford, MA) and immunoblotted with anti-p21 mouse monoclonal antibody (BD Biosciences, Bedford, MA). Immunodetection was performed using horseradish peroxidaseconjugated secondary antibody and ECL western blotting detection reagent (GE Healthcare, Buckinghamshire, UK) on a luminescent image analyzer (LAS-1000 plus; Fuji Film, Tokyo, Japan). The densities of p21 protein bands were analyzed using Image Gauge ver.3.4 software (Fuji Film).
Tumor induction and transplantation
Male and female transgenic mp53 mice and wild-type mice born from the same parents were used for tumor induction experiments. The MCA (Sigma-Aldrich) was dissolved in olive oil at 0.2 mg ml À1 and 0.1 ml of this solution was injected into the right groins of the mice at 6-8 weeks of age after individual births throughout the seasons. Tumor formation was followed by palpation for 1 year. Tumor size was measured with calipers and tumor volume was calculated by ab 2 /2, where a and b are the lengths of the long and short axes, respectively. The day of tumor appearance was defined as the day when a tumor reached a diameter of 3 mm. When tumors were found at a larger size, this date was estimated by extrapolating tumor growth curve with a volume-doubling time of 2.5 days. 22 Tumors were sectioned, fixed with 10% formalin, stained with hematoxylin and eosin (HE) and examined histologically. Other pieces of tumors were frozen in liquid nitrogen, preserved at À80 1C and transplanted when needed. For transplantation, tumors were cut to an approximately 1 mm cube and subcutaneously transplanted in sex-matched C57BL/6J-Jcl mice using a transplantation needle with a 1.5 mm inner diameter. One of the tumors sensitive to siRNA (sequence siRNA no. 220, as described below) was transplanted serially and designated as a TT18 line.
siRNA design
The candidate nucleotide sequence for the siRNA was obtained by searching the nucleotide sequences of the chicken b-actin promoter and CMV-IE enhancer using the Qiagen program. The sequences with a high score were no. 169, CGCCAAUAGGGACUUUCCAdTdT/ UGGAAAGUCCCUAUUGGCGdTdT; no. 220, CUG CCCACUUGGCAGUACAdTdT/UGUACUGCCAAG UGGGCAGdTdT; no. 290, AUGGCCCGCCUGG CAUUAUdTdT/AUAAUGCCAGGCGGGCCAUdTdT, in the CMV-IE enhancer. A high scoring sequence was not found in the chicken b-actin gene promoter.
In vitro assay of siRNA suppression activity in HEK293 cells The pTE50 plasmids were introduced into HEK293 cells using Lipofectamine 2000 (Invitrogen), followed by selection for neo-resistant cells harboring pTE50. The cells carrying pTE50 were treated with 50 nM siRNA and 0.008% atelocollagen for 48 h at 37 1C in a humidified CO 2 incubator. Total RNA was then extracted by ISOGEN (Nippon Gene, Tokyo, Japan) and subjected to mRNA-selective PCR followed by an analysis of the products by 1% agarose gel electrophoresis. For the quantitative assay, HEK293 cells containing plasmid pCAHST-1, which carried the reporter gene human FGF4 cDNA inserted downstream of the chicken b-actin gene promoter and CMV-IE enhancer, were treated with 50 nM siRNA and TransIT-TKO (Mirus, Madison, WI) for 48 h at 371C (n ¼ 3). Total RNA was extracted using ISOGEN and treated with DNase using the TURBO-DNA free kit (Ambion, TX). RNA (2 mg) was used for the synthesis of cDNA with random primers. The cDNA was diluted 2.5-fold and 5 ml was subjected to quantitative PCR in a 50 ml reaction mixture using Platinum Quantitative PCR SuperMix-UDG (Invitrogen) and the TaqMan Gene Expression Assay (Applied Biosystems) specific for human FGF4 or GAPDH. Real-time PCR was carried out for 45 cycles of 95 1C for 15 s and 60 1C for 30 s using the ABI PRISM 7300 Sequence Detection System (Applied Biosystems). The FGF4 expression was normalized to GAPDH.
Delivery of siRNA to the tumor and follow-up Atelocollagen (Koken, Tokyo, Japan) was used to deliver siRNA to the tumors. 30 The siRNA no. 220 or nonspecific siRNA (Qiagen, cat. no. 1027281) at 0.15 mg ml À1 was mixed with an equal volume of 1% atelocollagen by gentle rotation for 20 min at 41C. Autochthonous tumors were selected for treatment when they grew to a diameter of 5 mm in a spherical shape suitable for the test. Transplanted tumors usually reached this size 10 days after transplantation. Tumors were subcutaneously injected with 0.2 ml of the siRNA/ atelocollagen mixture using a syringe with a 24G needle at 2-3 day intervals for a total of four injections into the tumor site. The change in the tumor size was followed by calipers measurements. The initial response was followed in both the autochthonous and transplanted tumors after the start of siRNA treatment and autochthonous tumors were followed for a cure until the death of the mice.
Apoptosis detection
Tumor tissue sections were treated by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (DeadEnd Fluorometric TUNEL System; Promega, Madison, WI) for 60 min at 37 1C to detect fragmented DNA, counterstained with 4 0 ,6-diamidino-2-phenylindole
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Statistical analysis of tumor incidence rate Cumulative tumor incidence was analyzed by the KaplanMeier method 35 using a computer program (SSSMCTK3; Esumi, Tokyo, Japan). The difference in tumor incidence rates was evaluated by the log-rank test. 33 to construct plasmid pTE50 (Figure 1a) . When pTE50 was introduced in cultured human HEK293 cells, the mutant p53 proteins were overexpressed as revealed by abundant mutant p53 proteins by western blotting (Supplementary Figure 1) . The 5.4 kb fragments of pTE50 cut with BamHI/PvuI were then introduced into mouse embryos at the early stage and 2 mice with the transgene were obtained out of 105 born mice, 1 of them which was male was used for breeding. The presence of the mp53 introduced into the mouse genome was confirmed by Southern blot analysis and genomic PCR on mouse tail DNA (Figure 1b) . The mRNA-selective PCR revealed that the full-length exon 2-11 mp53 was expressed in the transgenic mice (Figure 1c) . The expressions of wild-type p53, p21 and chicken b-actin in the mp53 mouse liver were also demonstrated. The presence of the 9 bp deletion from codon 191 to codon 193 in exon 6 of mp53 mice was confirmed with the genomic DNA (data not shown) and cDNA (Figure 1d ). Codon 191 was repeatedly confirmed in the wild-type mouse genomic DNA and cDNA to contain AGG (Arg) instead of CGG (Arg), which is present in the registered nucleotide sequence.
Results

Cloning of mutant
p53 cDNA and the generation of transgenic mice First, we cloned mutant p53 cDNA from a mouse skin tumor produced by repeated b-irradiation. 31 This mutant p53 contained the coding frame from exon 2 to exon 11 carrying a 9 bp deletion from codon 191 to codon 193 in exon 6, 32 which corresponds to the DNA-binding domain of the p53 protein. The 1.17 kb mutant p53 cDNA was inserted downstream to the chicken b-actin promoter combined with the CMV-IE enhancer in the 5.8 kb expression vector pCXN2
Suppressive effect of mp53 on p21 expression
The p53 gene activity controls the expression of the p21 gene in the ATM regulating molecular network, which is involved in checkpoint arrest of the cell cycle and cellular apoptosis. The mutant p53 could exert its activity over p21 expression in a dominant-negative manner. 12, 16, 36 We examined p21 expression in the mp53 mouse embryonic fibroblasts after irradiation with 7 Gy. The level of p21 protein in wild-type cells increased with time, reaching a peak 6 h after irradiation, whereas the level of p21 protein in mp53 cells increased only slightly at 3 h and then gradually decreased (Figure 2 ). These patterns indicate that the mutant p53 inhibits p21 expression in mp53 transgenic mice in a dominantnegative manner after irradiation.
Tumor induction in mp53 transgenic mice
The mp53 transgenic mice and wild-type mice from the same siblings were subjected to tumor induction experiments. Mice aged 6-8 weeks were subcutaneously injected in the right groin with 20 mg MCA and followed for 1 year. The MCA dose was chosen from the doseresponse data obtained with MCA-induced tumors in wild-type C3H/He mice 22 and was expected to result in a tumor incidence of 20-30%. Tumors produced with this MCA dose are monoclonal, as previously demonstrated with mosaic cell mice. 37 As shown in Figure 3 , tumors started to appear in both the mp53 and wild-type mice around day 60. The majority of tumors were fibrosarcomas of the skin, histologically. A few tumors were of other histological types, including 3 rhabdomyosarcomas and 2 squamous cell carcinomas out of the 51 tumors examined in mp53 mice and 2 rhabdomyosarcmas out of the 52 tumors examined in wild-type mice. Spontaneous tumors never appeared on the olive oil-treated groins of the mice. The final cumulative tumor incidence for the mp53 mice was 1.7-fold higher than that of wild-type mice (59 versus 34%; Po0.01). The excess tumors formed in the mp53 mice (42% of total tumors) are, therefore, thought to be dependent on the function of mutant p53. Male mp53 mice appeared to have a higher tumor Silencing mutant p53 transgene to suppress tumors H Tanooka et al incidence than female mp53 mice (68 versus 48%; Supplementary Figure 3 ), although this difference was not statistically significant. Seasonal variation in tumor incidence was also not statistically significant (data not shown). Metastasis was absent in the lung and liver at autopsy.
As the allelic loss of wild-type p53 tends to occur in tumors formed in p53 heterozygous mice with a mutation on one side, [10] [11] [12] we examined the loss of wild-type p53 alleles in tumors developed in the mp53 mice. As determined by PCR, the wild-type p53 gene was retained in all 20 MCA-induced tumors in the mp53 mice (data not shown). The expression of wild-type p53 mRNA in the representative tumor TT18 was shown for exon 4-6 (Figure 1c ) or full length (data not shown).
siRNA suppression of tumor growth
The MCA-induced tumors were subjected to siRNA suppression experiments. If the mp53-targeting siRNA is effective in suppressing the growth of mp53-dependent tumors, it would be expected that the estimated 42% of tumors produced in excess in these transgenic mice will respond to the treatment and regress or at least, stop growing.
We selected siRNA no. 220 from the three candidates to suppress mp53 expression in cultured HEK293 cells harboring pTE50 (Figure 4a ) using the dose-response range (Supplementary Figure 2) . The suppression activity of the siRNA was further confirmed with a reporter gene, human FGF4, ligated downstream of the same chicken b-actin promoter/CMV-IE enhancer as used for pTE50 in plasmid pCAHST-1. The quantitative real-time PCR analysis revealed 30% suppression (Po0.05), although the suppression was not complete in this system (Figure 4b) .
To deliver siRNA to target molecules, an atelocollagen system, in which siRNA was complexed to atelocollagen, making it resistant to degradation in vivo and allowing it to be delivered stably to tumor cells, was used. 29, 30 When tumors grew to a diameter of 5 mm (63 mm 3 in volume), siRNA no. 220-atelocollagen complex was injected into the site surrounding the subcutaneous solid tumor at 2-3 day intervals for a total of four injections. Control tumors were treated with negative control siRNA-atelocollagen complex. Treatments with siRNA no. 220 resulted in the suppression of the growth of 6 of 23 autochthonous tumors (26%) in the mp53 mice, including 4 regressions and 2 growth arrests (Figure 4 ). Negative control siRNA had no effect on 10 tumors (Supplementary Figure 4) . The regression of siRNA no. 220-sensitive tumors was rapid, and tumors became nonpalpable within 10 days of beginning of the siRNA treatment. Mice no. 1-4 survived without tumor recurrence for 110, 51, 116 and 91 days, respectively. In a strict sense, three cases, mice no. 1, 3 and 4 fit the definition of a true cure, that is, the regression of a tumor without recurrence for 60 days, a time length long enough for a single surviving tumor cell to grow to a palpable size of 3 mm in diameter with a volume-doubling time of 2.5 days. 22 Mouse no. 1 exhibited residual cell debris at the site of the tumor (Supplementary Figure 5a) . The debris was stained with HE, indicating that the tumor existed there before treatment.
Another group of autochthonous tumors were individually transplanted into wild-type mice and then examined for a response to siRNA no. 220 after growing to a diameter of 5 mm. This treatment resulted in 7 responses among 21 transplants (33%). The tumor response data are summarized in Table 1 . To judge the initial tumor response, the results of the transplanted tumors were combined with the results of autochthonous tumors (26%); 30% of 44 tumors in total responded to siRNA no. 220 treatment. This efficiency is approximately comparable with the population of mp53-dependent tumors; 42% of total tumors produced in the mp53 mice. None of the wild-type tumors, either autochthonous or transplanted, responded to siRNA no. 220 (Table 1) .
One of the tumor transplant lines, TT18, which was confirmed to be siRNA no. 220-sensitive, was observed more extensively for a response to siRNA no. 220. In TT18, the expression profiles of mp53 and wild-type p53 mRNAs were essentially the same as in the liver of an mp53 mouse (Figure 1c ) and genomic wild-type p53 was preserved, as confirmed by PCR (data not shown). The TT18 tumor, after grown to a diameter of 5 mm, responded to siRNA no. 220 but not to negative control siRNA (Figure 5a) . A necrotic change occurred after the treatment of TT18 with siRNA no. 220 ( Supplementary  Figures 5b and 5c) . Concomitant with the suppression of tumor growth, the expression of mp53 mRNA in TT18 was suppressed by treatment with siRNA no. 220 (Figure 5b) . Strikingly, marked apoptosis was induced in the tumor mass during tumor regression (Figures 5c  and d) . Moreover, accompanied by apoptosis induction, the tissue structure of the fibrosarcoma disappeared, as demonstrated by the loss of the dense and fibrous tumor structure (Figures 5e and f) .
To obtain direct evidence that siRNA no. 220 completely suppresses the growth of an mp53-responsive tumor without the influence of other factors, a piece of Silencing mutant p53 transgene to suppress tumors H Tanooka et al the TT18 tumor was transplanted into the right groin of a mouse and another piece was transplanted into the left groin of the same mouse. Two days after transplantation, siRNA no. 220-atelocollagen was injected twice, at a 2-day interval, into the right transplantation site, and nonspecific siRNA-atelocollagen was simultaneously injected into the left site. Only the tumor injected with siRNA no. 220 did not grow in the right groin, whereas the tumor in the left groin injected with nonspecific siRNA grew to a diameter of 1.1 cm after 17 days, demonstrating that, in the same host, siRNA no. 220 exerts a suppressive effect at the site of injection and no effect at the site distant from the injection site in the same host. These results confirmed the effective suppression of mp53-dependent tumor growths by silencing the mp53 transgene with siRNA no. 220 in the presence of wild-type p53.
Discussion
If mutation in the p53 gene is a true cause of tumors, mice carrying mutant p53 must have a high incidence of tumor development. This theme has been addressed and pursued in heterozygous mice with a p53 mutation located in different codons corresponding to the DNA-binding domain of p53 proteins: codon 135, 16 These studies have shown that these p53 mutations cause tumors.
In this study, we employed transgenic mice hemizygous for mutant p53 carrying a deletion of codons 191-193 and retaining the wild-type p53 alleles. The transgenic mice expressed both mutant p53 mRNA and wild-type p53 mRNA (Figure 1) . The dominant-negative activity of mutant p53 on p21 protein expression was confirmed in irradiated fibroblasts from the mice (Figure 2 ). It was expected that, during the course of tumorigenesis, the function of wild-type p53 protein would be suppressed in the transgenic mice. If the functional loss of wild-type p53 protein is responsible for tumor induction to any extent, the transgenic mice would be significantly prone to tumor induction. Consistent with this expectation, the mutant p53 transgenic mice exhibited a significantly higher susceptibility to the chemical induction of tumors: a 1.7-fold increase in tumor incidence relative to wild-type mice when comparing the equivalent tumor induction procedure. Tumors appeared to be of two types: mutant p53 dependent (42%) and independent. If all mutant p53-dependent tumors respond to the silencing of the mutant p53, then 42% of the total tumors produced in the transgenic mice were expected to respond and consequently regress or stop growing on siRNA treatment. The Silencing mutant p53 transgene to suppress tumors H Tanooka et al actual gain of the response was 30% (Table 1) , which seems to fit this expectation by taking into account the suppression efficiency of siRNA no. 220. The same timing for tumor appearance in mp53 and wild-type mice ( Figure 3 ) implies an essentially equal length of latency, indicating that the tumor increase in mp53 mice is due to the attenuated function of wild-type p53 in apoptosis. If the mutation affects other functions, such as cell-cycle checkpoint control or DNA repair, tumor appearance would be accelerated with a shorter latency. In other aspects of this tumor system, MCA-induced autochthonous tumors have been a model target for experimental therapy, but curing theme is very difficult. Nakahara 21 stressed the importance of using autochthonous tumors to test agents to determine for a cure of tumors. Recently, the suppression of MCA-induced autochthonous tumors was made possible by treatment with a combination of three antibodies. 38 In this study, a further possibility was provided by gene silencing using siRNA combined with an atelocollagen delivery system. The siRNA was used to distinguish between mutant p53 and wild-type p53. Atelocollagen was used to protect the siRNA from RNase attack and to efficiently deliver siRNA to the target molecules. Additionally, its cellular toxicity is weak, whereas many transfection agents are highly toxic. The tumor-specific delivery of siRNA by atelocollagen to metastatic mouse tumors in vivo has been demonstrated. 30 In this study, this delivery system was useful when applied to subcutaneous solid tumors. Using this method, siRNA no. 220 effectively suppressed the growth of mp53-dependent tumors induced with MCA, apparently overcoming the difficulty of the character of the autochthonous tumor. Although we observed only few cases of a true cure, in the strict sense, we consider these cases provide a hope for future study.
Furthermore, the transplanted tumor TT18 exhibited a drastic apoptosis induction in response to treatment with siRNA no. 220 (Figure 5c and d) . This apoptosis induction is thought to be due to the restoration of wild-type p53 activity that had been suppressed by adding mutant p53. In human and mouse tumors caused by p53 mutation, the loss of wild-type p53 often occurs during tumorigenesis, so that the restoration of apoptotic activity through the reactivation of wild-type p53 function is impossible. In such a case, it will be necessary to further develop a molecular devise to compensate for wild-type p53 function or to activate apoptosis by other means.
In conclusion, we demonstrated that the mutant p53 with a 9 bp deletion in exon 6 elevates tumor incidence in the presence of wild-type p53 alleles, and that these tumors can be suppressed by silencing the mutant p53 transgene and, thereby, reactivating the apoptotic capacity. The results point out a new and promising modality toward the cure of human cancers, especially when the causative overexpressing gene can be identified.
